Sökning: WFRF:(Angelousi Anna)
> (2019) >
Activity and Safety...
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
-
- Chatzellis, Eleftherios (författare)
- Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece;251 HAF & VA Hosp, Athens, Greece
-
- Angelousi, Anna (författare)
- Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece
-
- Daskalakis, Kosmas (författare)
- Uppsala universitet,Endokrinkirurgi,Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece
-
visa fler...
-
- Tsoli, Marina (författare)
- Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece
-
- Alexandraki, Krystallenia I. (författare)
- Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece
-
- Wachula, Ewa (författare)
- Med Univ Silesia, Dept Clin Oncol & Radiotherapy, Katowice, Poland
-
- Meirovitz, Amichay (författare)
- Hadassah Hebrew Univ Med Ctr, Dept Oncol, Jerusalem, Israel;Hadassah Hebrew Univ Med Ctr, Radiat Therapy Unit, Jerusalem, Israel
-
- Maimon, Ofra (författare)
- Hadassah Hebrew Univ Med Ctr, Dept Oncol, Jerusalem, Israel;Hadassah Hebrew Univ Med Ctr, Radiat Therapy Unit, Jerusalem, Israel
-
- Grozinsky-Glasberg, Simona (författare)
- Hadassah Hebrew Univ Med Ctr, Dept Endocrinol & Metab, Neuroendocrine Tumour Unit, Jerusalem, Israel
-
- Gross, David (författare)
- Hadassah Hebrew Univ Med Ctr, Dept Endocrinol & Metab, Neuroendocrine Tumour Unit, Jerusalem, Israel
-
- Kos-Kudla, Beata (författare)
- Med Univ Silesia, Dept Endocrinol & Neuroendocrine Neoplasms, Dept Endocrinol & Pathophysiol, Katowice, Poland
-
- Koumarianou, Anna (författare)
- Univ Athens, Attikon Univ Gen Hosp, Hematol Oncol Unit, Dept Internal Med 4, Athens, Greece
-
- Kaltsas, Gregory (författare)
- Univ Athens, Dept Propaedeut Internal Med 1, Athens, Greece
-
visa färre...
-
(creator_code:org_t)
- 2019-06-03
- 2019
- Engelska.
-
Ingår i: Neuroendocrinology. - : S. Karger. - 0028-3835 .- 1423-0194. ; 109:4, s. 333-345
- Relaterad länk:
-
https://www.karger.c...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Capecitabine and temozolomide combination (CAPTEM) is associated with high response rates in patients with advanced neuroendocrine neoplasms (NENs). We evaluated the real-world activity and safety of CAPTEM from 3 NEN centers. Methods: Clinicopathological characteristics and outcomes of patients treated with CAPTEM for bulky or progressive disease (PD) were retrospectively analyzed. -Results: Seventy-nine patients with gastroenteropancreatic (grades 1-2 [n = 38], grade 3 [n = 24]) and lung/thymic (n = 17) NENs were included. Median treatment duration was 12.1 months (range 0.6-55.6). Overall, partial responses (PRs) occurred in 23 (29.1%), stable (SD) in 24 (30.4%), and PD in 28 (35.4%) patients. Median progression-free survival (PFS) and overall survival (OS) were 10.1 (6-14.2) and 102.9 months (43.3-162.5), respectively. On univariate analysis, NENs naive to chemotherapy and low Ki67 were associated with favorable responses (partial response [PR] + SD; p = 0.011 and 0.045), PFS (p < 0.0001 and 0.002) and OS (p = 0.005 and 0.001). Primary site (pancreas and lung/thymus) was also a significant prognostic factor for PFS (p < 0.0001) and OS (p < 0.0001). On multivariate analysis, gastrointestinal and unknown primary NENs (hazard ratio [HR] 0.3, 95% CI 0.1-0.8, p = 0.009 and p = 0.018) and prior surgery (HR 2.4, 95% CI 11-4.9, p = 0.021) were independent prognostic factors for PFS. Ki-67 was a poor predictor for favorable response in receiver operating characteristic analysis (area under the curve 0.678). Safety analysis of CAPTEM indicated rare events of serious (grades 3-4) toxicities (n = 4) and low discontinuation rates (n = 8) even in patients with prolonged administration (>12 months). Conclusions: CAPTEM treatment can be an effective and safe treatment even after prolonged administration for patients with NENs of various sites and Ki67 labeling index, associated with significant favorable responses and PFS.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Nyckelord
- Temozolomide
- Capecitabine
- Capecitabine and temozolomide combination
- TEMCAP
- Neuroendocrine neoplasms
- Neuroendocrine tumors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Chatzellis, Elef ...
-
Angelousi, Anna
-
Daskalakis, Kosm ...
-
Tsoli, Marina
-
Alexandraki, Kry ...
-
Wachula, Ewa
-
visa fler...
-
Meirovitz, Amich ...
-
Maimon, Ofra
-
Grozinsky-Glasbe ...
-
Gross, David
-
Kos-Kudla, Beata
-
Koumarianou, Ann ...
-
Kaltsas, Gregory
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
- Artiklar i publikationen
-
Neuroendocrinolo ...
- Av lärosätet
-
Uppsala universitet